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AbsTrACT
Importance Genetic testing of hereditary cancer 
using comprehensive gene panels can identify patients 
with more than one pathogenic mutation in high 
and/or moderate-risk-associated cancer genes. this 
phenomenon is known as multilocus inherited neoplasia 
alleles syndrome (MINAS), which has been potentially 
linked to more severe clinical manifestations.
Objective to determine the prevalence and clinical 
features of MINAS in a large cohort of adult patients 
with hereditary cancer homogeneously tested with the 
same gene panel.
Patients and methods A cohort of 1023 unrelated 
patients with suspicion of hereditary cancer was 
screened using a validated panel including up to 
135 genes associated with hereditary cancer and 
phakomatoses.
results thirteen (1.37%) patients harbouring two 
pathogenic mutations in dominant cancer-predisposing 
genes were identified, representing 5.7% (13/226) of 
patients with pathogenic mutations. Most (10/13) of 
these cases presented clinical manifestations associated 
with only one of the mutations identified. one case 
showed mutations in MEN1 and MLH1 and developed 
tumours associated with both cancer syndromes. 
Interestingly, three of the double mutants had a young 
age of onset or severe breast cancer phenotype and 
carried mutations in moderate to low-risk DNA damage 
repair-associated genes; two of them presented biallelic 
inactivation of CHEK2. We included these two patients 
for the sake of their clinical interest although we are 
aware that they do not exactly fulfil the definition of 
MINAS since both mutations are in the same gene.
Conclusions and relevance Genetic analysis of a 
broad cancer gene panel identified the largest series 
of patients with MINAS described in a single study. 
overall, our data do not support the existence of more 
severe manifestations in double mutants at the time of 
diagnosis although they do confirm previous evidence 
of severe phenotype in biallelic CHEK2 and other DNA 
repair cancer-predisposing genes.
InTrOduCTIOn
Hereditary cancer syndromes account for 5%–10% 
of all patients with cancer.1 Patients with these 
syndromes are carriers of pathogenic mutations 
in high or moderate-penetrance genes and are at 
risk of developing cancer at an early age as well as 
multiple synchronous or metachronous tumours. It 
is important to identify these patients because they 
will require specialised, long-term care and both 
they and their families can benefit from clinical 
follow-up appropriate to their risk, together with 
proper reproductive choices. One of the challenges 
in genetic counselling of these disorders is dealing 
with clinical heterogeneity and overlapping clinical 
manifestations. The phenotype variability could be 
explained by many factors, in isolation or in combi-
nation, such as incomplete penetrance, allelic and 
genetic heterogeneity, existence of genetic modi-
fiers, environmental factors and stochastic events.2 3 
Genetic diagnosis of these conditions has evolved 
over the last decade thanks to the introduction of 
next-generation sequencing, a cost-effective solu-
tion in terms of cost and time for the simultaneous 
sequencing of multiple genes. These new approaches 
for sequencing have led to the development of 
gene panels that contain clearly defined high-pene-
trance genes and moderate or even low-penetrance 
genes, arbitrary defined with a relative risk below 
4 (moderate) or 2 (low). The use of these genes 
in the clinical setting is a matter of discussion and 
some clinical geneticists and genetic counsellors are 
reluctant to screen them for clinical purposes due 
to the uncertainty of changing medical management 
in carriers and in non-carriers of mutations in these 
genes because clinical utility has not yet been clearly 
established.4 Moreover, the use of large gene panels 
can lead to unexpected and complex findings, for 
example, to identify patients with more than one 
pathogenic mutation in genes implicated in different 
cancer syndromes.5–7 The term ‘MINAS’ (multilocus 
inherited neoplasia alleles syndrome) was coined by 
Whitworth and colleagues8 in a JAMA Oncology 
review in which the authors presented their experi-
ence (five cases) and the literature review (82 cases) 
of patients with cancer with two pathogenic muta-
tions in hereditary cancer genes. No clear conclu-
sion was reached and a database was created to 
record such cases (http:// databases. lovd. nl/ shared/ 
diseases/ 04296); as of July 2018 it contained only 
40 entries, all but one from the Whitworth group. 
Very recently, the same group presented data from 
a series of 460 patients with two or more tumours 
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Table 1 Description of patients with MINAS identified
Id Phenotype Tumour/condition Age dx
Current age 
(β)/death (£) Mutation A* Mutation b*
Fam-1 AFAP Colorectal polyposis 76 77 (£) APC [c.423-3T>A; p.(Arg141Serfs*8)] BRCA1 [c.1961delA; p.(Lys654Serfs*47)]
Fam-2
(proband)











Fam-3 HBOC Ovarian cancer 45 51 (β) BRCA1 [c.607C>T; p.(Arg1203*)] TP53 [c.659A>G; p.(Tyr220Cys)]
Fam-4 Tuberous sclerosis Subcutaneous benign tumours
Epilepsy
6 28 (β) TSC2 [c.5227C>T; p.(Arg1743Trp)] RAD51D [c.694C>T; p.(Arg232*)]
Fam-5 Reed's syndrome Cutaneous leiomyomas 40 47 (β) FH (c.905-2A>G; p.?) BARD1 [c.157delT; p.(Cys53Valfs*5)]









HBOC Ovarian cancer 51 52 (β) BRCA1 [c.2309C>A; p.(Ser770*)] XPA [c.553C>T; p.(Gln185*)]
Fam-7
(sister)







68 (β) FLCN [c.346C>T;p.(Gln116*)] ERCC3 [c.325C>T;p.(Arg109*)]




59 (β) PALB2 [c.3256 C>T; p.(Arg1086*) ATM (c.3802delG;p.Val1268*)
Fam-10† HBOC Bilateral breast cancer 35 37 (β) CHEK2 (c.433C>T; p.(Arg145Trp)] CHEK2 [c.470T>C; p.(Ile157Thr)]
Fam-11† HBOC Breast cancer 42 42 (£) CHEK2 (whole gene deletion) CHEK2 [c.499G>A; p.(Gly167Arg)]
Fam-12 HBOC Breast cancer 35 38 (β) ATM [c.3712_3716del; 
p.(Leu1238Lysfs*6)]
FANCA (c.2602-1G>C; p.?)
Fam-13 HBOC Ovarian cancer 49 70 (β) SDHB [c.505C>T; p.(Gln169*)] FANCA [c.3558dupG; 
p.(Arg1187Glufs*28)]
*Cell shadow code: dark grey: high-risk genes, light grey: moderate to low-risk genes (see online supplementary table 1).
†These patients are compound heterozygous for mutations at the same time, therefore they do not strictly fulfil the MINAS first definition.
AFAP, attenuated familial adenomatous polyposis; HBOC, hereditary breast-ovarian cancer; HNPCC, hereditary non-polyposis colorectal cancer; MEN1, multiple endocrine neoplasia type 1; MINAS, 
multilocus inherited neoplasia alleles syndrome. 
The authors highlighted that data gathered in the literature 
presented inherent ascertainment bias in relation to the genes 
and patients analysed. Most of the cases studied in the prepanel 
era were patients with breast and ovarian or colorectal cancer, 
in which only a few suspected genes were analysed, hence 
most examples with double mutations are patients with two 
germline BRCA1 and BRCA2 mutations or with constitutional 
mismatch repair deficiency syndrome, the latter with a clearly 
defined severe phenotype.10–13 In addition, homozygosity for the 
founder c.1100delC CHEK2 mutation has been associated with 
high breast cancer risk relative to heterozygous carriers.14
We report the genotype and phenotype of the largest unbiased 
MINAS cohort of patients with hereditary cancer analysed with 
a comprehensive gene panel that includes almost all hereditary 
cancer genes described in the literature.
MATerIAls And MeThOds
Our study population is a cohort of 1023 unrelated adult 
patients with clinical suspicion of hereditary cancer, visited 
in the Genetic Counselling Unit of the Catalan Institute of 
Oncology. Institutional review board approval was obtained for 
panel testing. For genetic testing, we used our validated custom 
I2HCP gene panel (containing 122–135 genes, depending on 
the version used).15 Variant classification was conducted under 
American College of Medical Genetics and Genomics guide-
lines.16 When possible, cosegregation analysis was performed. 
A brief description of the whole cohort is depicted in online 
supplementary table 1 and online supplementary figure 1 
(comprehensive analysis is under publication, Feliubadaló et al, 
submitted manuscript). From our cohort of 1023 patients, 16% 
had multiple tumours. Of them, four patients are part of our 
MINAS series. For the purposes of this study, only patients with 
more than one pathogenic/likely pathogenic mutation (hereafter, 
‘mutation’) in dominant cancer-predisposing genes are presented 
(online supplementary table 2). All the mutations reported here 
were confirmed by Sanger sequencing. All patients underwent 
a tiered-binned informed consent process. Twenty-four of our 
135 panel genes were denominated CORE genes (Feliubadaló et 
al, submitted manuscript). Pathogenic variants in all these genes 
were returned to patients—including those with an unrelated 
phenotype, unless patients did not consent for the CORE panel 
analysis. The remaining genes of the panel were considered as 
research genes and are used for research purposes and the results 
are then explained to families in this scenario where cosegrega-
tion analysis is requested.
resulTs
We identified 13 unrelated patients carrying more than one 
mutation (1.37%) (table 1, figures 1 and 2), representing 5.75% 
of patients with pathogenic mutations in our study population 
(the overall mutation detection yield is 22.14%). The referral 
criteria for each are summarised in online supplementary table 1.
Nine patients had one high-risk gene mutation (Fam-1 
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Figure 1 pedigrees of MINAS patients. Filled quarters of symbols indicate affected patients (each color denotes a specific type of tumor). Current age, 
age at death and age at diagnosis, when available, are also detailed. proband is marked by an arrow, carrier status was studied in available relatives, and 
those carrying the variant are shown with the variant symbol (#,$) and if genotyped and not carriers a (-) is under the mutation symbol. A number inside a 
symbol denotes the number of siblings condensed in the symbol.  Brain C (light orange), BC: breast cancer (emerald), C pol: colon polyposis (light green), 
CrC: colorectal cancer (red), CUp: carcinoma of unknown primary (yellow), Kidney Cancer (black), Leiomyomas (light blue), Lymphoma (orange), Melanoma 
(brown), Net: neuroendocrine tumor (dark green), oC: ovarian cancer (blue), tuberous sclerosis (purple), UC: uterine carcinoma (pink). 
phenotype. The second mutation in these families did not trans-
late into recognised clinical manifestations, except for Fam-2, in 
which two sisters carry two high-risk mutations; one presented 
a phenotype consistent with the clinical features of both cancer 
syndromes (MLH1 and MEN1), whereas the other showed only 
MEN1 clinical traits. In Fam-7, two sisters with double mutations 
(BRCA1 and XPA) presented ovarian cancer at ages 37 and 51, 
respectively. It should be noted that in two additional patients 
the second mutation was in a high-risk gene (BRCA1 and TP53), 
whereas in the remainder the mutations were in genes associated 
with moderate or low risk of breast, ovarian or colorectal cancer 
(RAD51D, XPA, BARD1, EXO1, ATM and ERCC3).
Three cases (Fam-10 to Fam-12) with clinical suspicion of 
hereditary breast-ovarian cancer harbour two mutations in 
moderate to low breast cancer risk genes: one patient with muta-
tions in ATM and FANCA genes and two patients with biallelic 
mutations in CHEK2. Two of these patients were diagnosed with 
young-onset breast cancer (35 years) and the third was diag-
nosed with metastatic breast cancer at 42 years and had a poor 
outcome; none had a family history of breast cancer.
The last patient was diagnosed with ovarian cancer before the 
age of 50 and presented mutations in SDHB and FANCA, which 
are difficult to associate with the observed phenotype (Fam-13).
dIsCussIOn
The term MINAS was introduced with a view to discerning 
whether carriers of pathogenic mutations in more than one domi-
nant hereditary cancer gene have specific clinical characteristics 
or are associated with a more severe phenotype. In our series, 15 
patients from 13 families are carriers of two pathogenic muta-
tions in dominant hereditary cancer genes. The most common 
situation was the presence of a mutation in a high-risk gene 
associated with the proband’s cancer phenotype and a second 
mutation without current clinical manifestations in the proband 
or the family. A mixed clinical presentation was only observed 
in one family where one of carriers of MEN1 and MLH1 muta-
tions presented clinical traits of the two hereditary cancer condi-
tions. Interestingly, in three cases of early-onset breast cancer 
the proband carried two pathogenic mutations in moderate to 
low-risk genes, suggesting an additive effect of these two muta-
tions. This hypothesis merits further exploration and is addition-
ally supported by Dutch population data for the analysis of the 
founder c.1100delC CHEK2 mutation.14 It is important to note 
that the two patients who were compound heterozygotes for 
CHEK2 mutations do not fulfil the strict definition of MINAS 
made formerly since both mutations are in the same gene, but we 
really believe that the fact of observing a severe phenotype in the 
three instances with mutations in moderate to low cancer risk 
genes makes it worth highlighting as well as being documented 
together in the MINAS open database. Notably, we highlight the 
identification of mutations in known high-risk cancer-associated 
genes (such as BRCA1, TP53 or RAD51C) that, in this context of 
double mutations, behave as low-penetrance pathogenic variants 
with no personal or family cancer history. There are different 
possible reasons for this, such as young age of the proband, 
incomplete penetrance, a de novo mutation in the proband, 
genetic mosaicism, lower risk than expected for the specific 
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Figure 2 pedigrees of MINAS patients. Filled quarters of symbols indicate affected patients (each color denotes a specific type of tumor). Current age, age 
at death and age at diagnosis, when available, are also detailed. proband is marked by an arrow, carrier status was studied in available relatives, and those 
carrying the variant are shown with the variant symbol (#,$) and if genotyped and not carriers a (-) is under the mutation symbol. A number inside a symbol 
denotes the number of siblings condensed in the symbol. Bl C: bladder cancer (light yellow), BC: breast cancer (emerald), Bil BC: bilateral breast cancer 
(emerald), CrC: colorectal cancer (red), CUp: carcinoma of unknown primary (yellow), Kidney Cancer (black), LC: lung cancer (grey), Lymphoma (orange), 
Melanoma (brown), oC: ovarian cancer (blue), pC: pancreas cancer (light orange), Stomach cancer (light grey), tuberous sclerosis (purple), UC: uterine 
carcinoma (pink). 
Hopefully, these can be clarified with cosegregation data, func-
tional analysis or tumour profiling. In such situations, genetic 
counselling, clinical surveillance and cascade testing should be 
offered since these mutations are in genes of clearly known clin-
ical utility.
In conclusion, further analysis and prospective follow-up of 
these patients is needed to improve our knowledge of the clinical 
relevance and consequences of MINAS. Of potential clinical and 
scientific interest is the putative relation of double mutations in 
moderate to low cancer risk genes with a severe clinical pheno-
type in early onset of cancer. As suggested by Whitworth, sharing 
genetic and clinical data and the continuous clinical update of 
these patients is crucial. To this end, all our cases have been 
submitted to the open database created by Whitworth (https:// 
databases. lovd. nl/ shared/ diseases/ 04296).
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